Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer

Rosella Silvestrini, Maria Grazia Daidone, Giovanni Di Fronzo, Alberto Morabito, Pinuccia Valagussa, Gianni Bonadonna

Research output: Contribution to journalArticlepeer-review

Abstract

The paper analyzes the relation among tumor size (T), estrogen receptor (ER) status, and labeling index (LI) and their relative merits in predicting the relapse-free (RFS) and overall survival (OS) in 215 node-negative women with primary breast cancer. All patients were subjected to Halsted or modified radical mastectomy; none received postoperative irradiation or systemic adjuvant therapy. The 5-year RFS was 75.3% and OS 89.0% When singly tested, LI and ER were able to significantly predict RFS and OS. In contrast, T influenced only RFS but not OS. The multivariate analysis showed that, in the presence of the two other variables, only LI retained its prognostic significance both for time to relapse (p = 0.0044) and survival (p = 0.035). From the present findings, LI appears to be a new important prognostic variable in the selection of high risk patients for whom adjuvant systemic therapy should perhaps be part of their primary treatment.

Original languageEnglish
Pages (from-to)161-169
Number of pages9
JournalBreast Cancer Research and Treatment
Volume7
Issue number3
DOIs
Publication statusPublished - Oct 1986

Keywords

  • estrogen receptor
  • labeling index
  • node-negative breast cancer
  • prognosis
  • survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer'. Together they form a unique fingerprint.

Cite this